endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

9 years ago
R&D

No­var­tis’s block­buster CDK 4/6 con­tender LEE011 gets a VIP count­down at the FDA

9 years ago
Pharma

VIP Clin­ton sup­port­er pitched cam­paign chief Podes­ta on Cana­di­an price con­trols for the US

9 years ago
Pharma

What’s on Sanofi’s M&A list now that Medi­va­tion is gone? Cat­a­lyst gets an SPA; Adap­ti­m­mune part­ners with Mer­ck

9 years ago
News Briefing

NYC’s top re­search in­sti­tu­tions part­ner on Step 2 in build­ing a biotech hub

9 years ago
Startups

2016's drug pric­ing head­winds threat­en a hur­ri­cane of new reg­u­la­tions

9 years ago
Bioregnum
Pharma

Af­ter a se­ries of PI3k pile­ups, Genen­tech of­floads a PhII-ready ri­val for fire­sale price

9 years ago
R&D
Pharma

As­traZeneca R&D leader Pan­ga­los warns of a post-Brex­it UK re­search re­treat with­out re­im­burse­ment re­form

9 years ago
Pharma

In­flu­en­tial Third Rock Ven­tures marks a decade of high-pro­file wins and loss­es with record $616M Fund IV

9 years ago
Financing

Man­u­fac­tur­ing woes de­rail a block­buster con­tender from Sanofi/Re­gen­eron. Who's next?

9 years ago
R&D

Promi­nent MIT sci­en­tist Su­san Lindquist dies of can­cer; Elec­tion fears dam­ag­ing biotech stocks?; Promethera adds 10M ...

9 years ago
News Briefing

An­oth­er Ra­maswamy stunt plays well on Wall Street, Mar­tin Shkre­li on shame, and more

9 years ago
Bioregnum
Opinion

On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

9 years ago
R&D

In­dus­try vet Ken Moch jumps to the helm of a small biotech with big dreams for treat­ing Alzheimer’s

9 years ago
R&D

That En­gMab buy­out? Cel­gene agreed to pay up to $3B for BC­MA-tar­get­ing drug

9 years ago
Deals

FDA flash­es red light on Sanofi man­u­fac­tur­ing in­frac­tion, threat­en­ing a loom­ing block­buster de­ci­sion

9 years ago
Pharma

AS­CO star, backed by bil­lion­aires, goes to Astel­las in $1.4 bil­lion buy­out

9 years ago
Deals

Bil­lion­aire Be­zos, Arch car­ry a torch for ag­ing R&D, back $116M mega-round for Uni­ty

9 years ago
R&D

FDA slaps a par­tial hold on one of As­traZeneca's cru­cial dur­val­um­ab pro­grams

9 years ago
R&D

GSK dumps a late-stage HIV drug; MIT of­fers sup­port for tech start-ups; Ra Phar­ma clos­es flat af­ter $92M IPO

9 years ago
News Briefing

Pro­QR shares spike on pos­i­tive PoC study for lead CF drug

9 years ago
R&D

Bruised by a pun­ish­ing Op­di­vo fail­ure, Bris­tol-My­ers looks to shake up the busi­ness, ac­cel­er­ate R&D

9 years ago
R&D

Al­ler­gan’s ex­ec­u­tive team or­ches­trates a $200M buy­out to beef up gas­troen­terol­o­gy pipeline

9 years ago
Deals

Turn­ing phar­ma castoffs in­to an in­stant for­tune, Vivek Ra­maswamy’s My­ovant bags a $218M IPO

9 years ago
Financing
First page Previous page 1159116011611162116311641165 Next page Last page
A service from the Financial Times